Literature DB >> 24996516

Hospitalization stay and costs attributable to Clostridium difficile infection: a critical review.

L Gabriel1, A Beriot-Mathiot2.   

Abstract

In most healthcare systems, third-party payers fund the costs for patients admitted to hospital for Clostridium difficile infection (CDI) whereas, for CDI cases arising as complications of hospitalization, not all related costs are refundable to the hospital. We therefore aimed to critically review and categorize hospital costs and length of hospital stay (LOS) attributable to Clostridium difficile infection and to investigate the economic burden associated with it. A comprehensive literature review selected papers describing the costs and LOS for hospitalized patients as outcomes of CDI, following the use of statistics to identify costs and LOS solely attributable to CDI. Twenty-four studies were selected. Estimated attributable costs, all ranges expressed in US dollars, were $6,774-$10,212 for CDI requiring admission, $2,992-$29,000 for hospital-acquired CDI, and $2,454-$12,850 where no categorization was made. The ranges for LOS values were 5-13.6, 2.7-21.3, and 2.8-17.9 days, respectively. The categorization of CDI attributable costs allows budget holders to anticipate the cost per CDI case, a perspective that should enrich the design of appropriate incentives for the various budget holders to invest in prevention so that CDI prevention is optimized globally.
Copyright © 2014 The Healthcare Infection Society. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Clostridium difficile; Cost of disease; Economic burden; Hospital costs; Hospital length of stay; Nosocomial

Mesh:

Year:  2014        PMID: 24996516     DOI: 10.1016/j.jhin.2014.04.011

Source DB:  PubMed          Journal:  J Hosp Infect        ISSN: 0195-6701            Impact factor:   3.926


  26 in total

1.  Comparison of laparoscopic versus open gastrectomy for advanced gastric cancer: an updated meta-analysis.

Authors:  Yingjun Quan; Ao Huang; Min Ye; Ming Xu; Biao Zhuang; Peng Zhang; Bo Yu; Zhijun Min
Journal:  Gastric Cancer       Date:  2015-07-28       Impact factor: 7.370

2.  Burden of Clostridium difficile infection between 2010 and 2013: Trends and outcomes from an academic center in Eastern Europe.

Authors:  Zsuzsanna Kurti; Barbara D Lovasz; Michael D Mandel; Zoltan Csima; Petra A Golovics; Bence D Csako; Anna Mohas; Lorant Gönczi; Krisztina B Gecse; Lajos S Kiss; Miklos Szathmari; Peter L Lakatos
Journal:  World J Gastroenterol       Date:  2015-06-07       Impact factor: 5.742

3.  Is Clostridium difficile the new bugaboo after cardiac surgery?

Authors:  Simona Silvetti; Giovanni Landoni
Journal:  J Thorac Dis       Date:  2018-09       Impact factor: 2.895

Review 4.  Reducing Clostridium difficile in the Inpatient Setting: A Systematic Review of the Adherence to and Effectiveness of C. difficile Prevention Bundles.

Authors:  Anna K Barker; Caitlyn Ngam; Jackson S Musuuza; Valerie M Vaughn; Nasia Safdar
Journal:  Infect Control Hosp Epidemiol       Date:  2017-03-27       Impact factor: 3.254

5.  Incidence and economic burden of Clostridioides difficile infection in Ontario: a retrospective population-based study.

Authors:  Jennifer A Pereira; Allison McGeer; Antigona Tomovici; Alex Selmani; Ayman Chit
Journal:  CMAJ Open       Date:  2020-01-30

Review 6.  Clostridium difficile infection.

Authors:  Wiep Klaas Smits; Dena Lyras; D Borden Lacy; Mark H Wilcox; Ed J Kuijper
Journal:  Nat Rev Dis Primers       Date:  2016-04-07       Impact factor: 52.329

7.  Utilization of Health Services Among Adults With Recurrent Clostridium difficile Infection: A 12-Year Population-Based Study.

Authors:  Jennifer L Kuntz; Jennifer M Baker; Patricia Kipnis; Sherian Xu Li; Vincent Liu; Yang Xie; Stephen Marcella; Gabriel J Escobar
Journal:  Infect Control Hosp Epidemiol       Date:  2016-10-20       Impact factor: 3.254

8.  Proton Pump Inhibitors Do Not Increase Risk for Clostridium difficile Infection in the Intensive Care Unit.

Authors:  David M Faleck; Hojjat Salmasian; E Yoko Furuya; Elaine L Larson; Julian A Abrams; Daniel E Freedberg
Journal:  Am J Gastroenterol       Date:  2016-08-30       Impact factor: 10.864

9.  Toxin A-negative toxin B-positive ribotype 017 Clostridium difficile is the dominant strain type in patients with diarrhoea attending tuberculosis hospitals in Cape Town, South Africa.

Authors:  B Kullin; J Wojno; V Abratt; S J Reid
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-09-30       Impact factor: 3.267

10.  Characterisation of Clostridium difficile strains isolated from Groote Schuur Hospital, Cape Town, South Africa.

Authors:  B Kullin; T Brock; N Rajabally; F Anwar; G Vedantam; S Reid; V Abratt
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-07-27       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.